PIAS1抗体;PIAS1 Antibody—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Rat liver tissue lysate, Primary antibody: P10720(FGF3 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P10720(FGF3 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P10720(FGF3 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

The PIAS1 (Protein Inhibitor of Activated STAT1) antibody is a crucial tool in studying the PIAS1 protein, a member of the PIAS family that regulates diverse cellular processes. PIAS1 functions as a SUMO (Small Ubiquitin-like Modifier) E3 ligase, facilitating SUMOylation of target proteins, including transcription factors like STAT1. NF-κB, and p53. It modulates transcriptional activation, chromatin remodeling, and signal transduction pathways involved in inflammation, immunity, apoptosis, and stress responses. PIAS1 also interacts with nuclear receptors and plays roles in maintaining genomic stability. Dysregulation of PIAS1 is implicated in cancers, autoimmune diseases, and neurodegenerative disorders.

The PIAS1 antibody enables detection and analysis of PIAS1 expression, localization, and protein interactions in techniques such as Western blotting, immunoprecipitation, immunofluorescence, and chromatin immunoprecipitation (ChIP). Researchers use it to explore PIAS1's role in disease mechanisms, such as its tumor-suppressive or oncogenic effects in different cancers, or its modulation of inflammatory signaling (e.g., JAK-STAT, NF-κB). Commercially available PIAS1 antibodies are typically raised in rabbits or mice, with validation via knockout cell lines or siRNA knockdown to ensure specificity. Its application advances understanding of post-translational modifications, transcriptional regulation, and therapeutic targeting of PIAS1-associated pathways.